Barranco-Fragoso B, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 148-149
Archivo PDF: 65.94 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.

2. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 31: 470-7.

3. Kanwal F, White DL, Tavakoli-Tabasi S, Jiao L, Lin D, Ramsey DJ, Spiegelman A, et al. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol 2014; 12: 327-33.

4. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014; 109: 1576-84.

5. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.

6. Ford E, Giles H, Mokdad A. Increasing prevalence of the metabolic syndrome among U.S. adults. Diab Care 2004; 27: 2444-9.

7. Wu TW, Chan HL, Hung CL, Lu IJ, Wang SD, Wang SW, Wu YJ, et al.; MAGNET Study Investigator. Differential patterns of effects of age and sex on metabolic syndrome in Taiwan: implication for the inadequate internal consistency of the current criteria. Diabetes Res Clin Pract 2014; 105: 239-44.